Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders (Q39482244)

12 September 2017

1 reference

title

Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders (English)

1 reference

12 September 2017

1 reference

1 reference

C M Spencer

1

1 reference

12 September 2017

D Faulds

series ordinal

2

1 reference

12 September 2017

language of work or name

1 reference

1 September 1994

1 reference

12 September 2017

1 reference

12 September 2017

48

1 reference

12 September 2017

3

1 reference

12 September 2017

404-430

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199448030-00007

12 September 2017

0 references

cites work

Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastrin cells and somatostatin cells in the rat stomach

1 reference

12 December 2020

Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment

1 reference

12 December 2020

Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells

1 reference

12 December 2020

Activity of lansoprazole against Helicobacter pylori

1 reference

12 December 2020

Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer

1 reference

12 December 2020

Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease

1 reference

12 December 2020

Effect of short- and long-term treatment with omeprazole on cell cycle distribution in the gastric mucosa. Results of a flow cytometric study

1 reference

12 December 2020

Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole

1 reference

12 December 2020

Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome.

1 reference

12 December 2020

Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders

1 reference

12 December 2020

Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells

1 reference

12 December 2020

Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats

1 reference

12 December 2020

Role of acid suppressants in patients with Zollinger-Ellison Syndrome

1 reference

12 December 2020

Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis.

1 reference

12 December 2020

Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group

1 reference

12 December 2020

Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine

1 reference

12 December 2020

Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses

1 reference

12 December 2020

Lansoprazole and Helicobacter pylori infection

1 reference

12 December 2020

1 reference

12 December 2020

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori

1 reference

12 December 2020

Campylobacter pylori: its link to gastritis and peptic ulcer disease.

1 reference

12 December 2020

Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats

1 reference

12 December 2020

An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment

1 reference

12 December 2020

Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial

1 reference

12 December 2020

Influence of lansoprazole treatment on diazepam plasma concentrations

1 reference

12 December 2020

Focal oxyntic gland atrophy with endocrine cell hyperplasia in Zollinger-Ellison syndrome during omeprazole treatment

1 reference

12 December 2020

Does lansoprazole influence postprandial digestive function?

1 reference

12 December 2020

Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12)

1 reference

12 December 2020

Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial

1 reference

12 December 2020

Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity

1 reference

12 December 2020

Effect of lansoprazole on intragastric pH. Comparison between morning and evening dosing

1 reference

12 December 2020

Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration

1 reference

12 December 2020

Human gastric acid secretion following repeated doses of AG-1749.

1 reference

12 December 2020

The H+,K+-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole

1 reference

12 December 2020

Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine.

1 reference

12 December 2020

Clinical effect of proton pump inhibitors on reflux esophagitis

1 reference

12 December 2020

Dose ranging study of lansoprazole, a new proton pump inhibitor, in patients with high gastric acid secretion.

1 reference

12 December 2020

Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome

1 reference

12 December 2020

Session 6: Is Hypergastrinaemia Dangerous to Man?

1 reference

12 December 2020

Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus.

1 reference

12 December 2020

Proton-Pump Inhibition for Acid-Related Disease

1 reference

12 December 2020

Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders

1 reference

12 December 2020

[Activity of Lansoprazole (new proton pump inhibitor) against Helicobacter pylori and its therapeutic efficacy].

1 reference

12 December 2020

Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome. Influence of gastrinoma growth and long-term omeprazole treatment.

1 reference

12 December 2020

[In vitro anti-microbial activity against H. pylori and clinical efficacy of various drugs]

1 reference

12 December 2020

The effects of lansoprazole, a new H+,K+-ATPase inhibitor, on gastric pH and serum gastrin

1 reference

12 December 2020

Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole

1 reference

12 December 2020

1 reference

12 December 2020

Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs

1 reference

12 December 2020

Proton pump inhibitors in the treatment of peptic ulcers resistant to H2-receptor antagonists

1 reference

12 December 2020

Short report: treatment of gastric ulcer with lansoprazole or ranitidine: a multicentre clinical trial

1 reference

12 December 2020

Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases

1 reference

12 December 2020

H2-receptor antagonist-refractory ulcer: its pathophysiology and treatment

1 reference

12 December 2020

The effects of lansoprazole, 30 or 60 mg daily, on intragastric pH and on endocrine function in healthy volunteers

1 reference

12 December 2020

Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749.

1 reference

12 December 2020

Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects

1 reference

12 December 2020

Rapid healing of gastric ulcers with lansoprazole

1 reference

12 December 2020

The effect of food and antacids on lansoprazole absorption and disposition

1 reference

12 December 2020

Barrett's oesophagus and carcinoma. Recent insights into its development and possible prevention.

1 reference

12 December 2020

Safety of lansoprazole.

1 reference

12 December 2020

10.2165/00003495-199448030-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

12 September 2017

0 references

1 reference